News
Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan
China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most Favored Nation executive order; FDA Commissioner Marty Makary and CBER director Vinay Prasad reveal new COVID-19 vaccine strategy following Novavax approval;
Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 ...
Moscicki previously served as the deputy center director for science operations at the FDA’s Center for Drug Evaluation and ...
Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.
SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, ...
Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies, to the pipeline, following a major trial setback this ...
An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.
Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...
Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback